Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, provided his clinical perspective on role of imaging and viral infections in patients with MS at the 2023 ACTRIMS forum.

A group of experts in the care of patients with multiple sclerosis—Marisa McGinley, DO; Farrah Mateen, MD, PhD; Laura Piccio, MD, PhD; Robert Zivadinov, MD, PhD; and Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management from the 2023 ACTRIMS Forum.

The clinical research director of the UCSF Multiple Sclerosis Center spoke about the barriers in accessing proven therapies for NMOSD at the 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Rajiv Jain, PhD, post-doctoral associate, department of clinical neurosciences, University of Calgary, talked about his presentation on T-bet+ memory B-cells in multiple sclerosis at the 2023 ACTRIMS Forum.

The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]

Taylor Gonyou, DO, a multiple sclerosis fellow at Michigan Institute for Neurologic Disorders, detailed a proteomic biomarker panel that gauges multiple sclerosis disease activity, with potential to impact clinical decision-making.

The director of the Buffalo Neuroimaging Analysis Center provide perspective on innovative ways to monitor progression in multiple sclerosis, and the importance of high-level care facilities. [WATCH TIME: 5 minutes]

Svetlana P. Eckert, MD, clinical assistant professor of neurology at University at Buffalo, talked about Evusheld as a preventive approach to COVID-19 infections in multiple sclerosis at the 2023 ACTRIMS Forum.

At the 2023 ACTRIMS Forum, the clinical research director of the UCSF Multiple Sclerosis Center talked about the implications for patients on B-cell depleting therapies infected with COVID-19. [WATCH TIME: 4 minutes]

Nine of the 10 participants with NMOSD included in the case series have remained relapse-free after switching to satrlizumab from previous therapy.

The clinical research director of the UCSF Multiple Sclerosis Center spoke on the findings from two post-hoc analyses that were presented at the 2023 ACTRIMS Conference. [WATCH TIME: 3 minutes]

Of 2 patient fatalities in the analysis, one was unvaccinated and treated with nonconventional therapies for COVID-19 and the other had a history of deep venous thrombosis and was complicated by pulmonary embolism.

The director of the Buffalo Neuroimaging Analysis Center discussed the need to further explain differences in cortical lesions and deep gray matter in patients with severely affected multiple sclerosis. [WATCH TIME: 4 minutes]

Bruce Cree, MD, PhD, MAS, FAAN, clinical research director of the UCSF Multiple Sclerosis Center provided insight on 2 post-hoc analyses of the N-MOmentum trial for NMOSD that were presented at 2023 ACTRIMS Forum.

The neurologist and physician scientist at Washington University in St. Louis provided insight on the general dieting strategies patients with multiple sclerosis should take as more information becomes available. [WATCH TIME: 6 minutes

As a recap from ACTRIMS 2023, get caught up on some of the latest news in multiple sclerosis as the NeurologyLive® team shares some of our data updates.

The associate director of the Multiple Sclerosis & Neuromyelitis Optica Unit at Massachusetts General Hospital provided perspective on a study that linked NMOSD to increased unemployment and decreased income. [WATCH TIME: 6 minutes]

The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic discussed how patients with multiple sclerosis are more open to using telehealth for accessing their healthcare providers at the 2023 ACTRIMS Forum. [WATCH TIME: 4 minutes]

The director of the Buffalo Neuroimaging Analysis Center provided context on the CASA-MS study, and the key differences in why certain patients with multiple sclerosis experience more rapid disability progression. [WATCH TIME: 4 minutes]

Compared with those on an unrestricted diet, patients with MS on intermittent calorie restriction showed greater cognitive performance, as assessed by SDMT, after 12 weeks dieting.

At the 2023 ACTRIMS Forum, the staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic talked about the lack of trust and engaging more with the MS community. [WATCH TIME: 5 minutes]

The ozanimod group demonstrated significantly lower odds of safety outcomes such as nasopharyngitis, diarrhea, and urinary tract infection relative to diroximel fumarate.

The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke at the 2023 ACTRIMS Forum about disparities in care access for patients with MS. [WATCH TIME: 5 minutes]

An ad hoc analysis of patients from a pair of phase 3 clinical trials and an open-label extension suggest that more than 5 years of treatment with ozanimod (Zeposia; BMS) was safe, without differences in age groups.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of ACTRIMS.

Results from the open-label SAkuraMoon study show consistent relapse freedom in satralizumab-treated patients with aquaporin-4-IgG-seropositive NMOSD.

Treatment with either rituximab and ocrelizumab, 2 FDA-approved therapies that target CD20, resulted in similar odds of experiencing a clinical disease activity in both unadjusted and adjusted analyses.

A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized neuroinflammation in multiple sclerosis compared with anti-CD20 treatment.

An analysis of patients with MOGAD showed that only 50% of those treated with various immunotherapies over a long-term period maintained relapse-free status.

Between pretreatment naïve patients and those previously on disease-modifying therapies, treatment with cladribine resulted in stable scores on Symbols Digit Modalities Test and other cognitive assessments.